Teva Pharmaceutical Industries Ltd. ADR 1.14% $25.35B ...

Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...

After hours: December 27 at 7:38:58 PM EST Loading Chart for GSK ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

GSK has terminated a phase 1/2 hepatitis B trial after the therapeutic vaccine regimen failed to meet the efficacy endpoint, denting the company’s hopes of creating a functional cure for the ...

GSK has made another trip to China to build out its antibody-drug conjugate (ADC) pipeline, returning with an option on a preclinical Duality Biologics candidate that could ultimately cost the Big ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of £16.90. The company’s shares closed today at p1,321. ...

LONDON — A blood cancer treatment from GSK helped patients live longer in a pivotal trial, a significant finding as the once-withdrawn drug mounts a comeback. In the study, a treatment ...

GSK has acquired exclusive global rights to progress the clinical development and commercialisation of GSK’227. Credit: MAXSHOT.PL/Shutterstock. GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today. The company’s shares opened today at p1,388.50. Pick the best stocks and maximize ...